TDP-43 Accumulation Potential Indicator for Patients with ALS
Posted on 07 Jun 2022
Amyotrophic lateral sclerosis (ALS) is a clinical diagnosis based on a history of progressive motor dysfunction that demonstrates a combination of upper motor neuron (UMN) and lower motor neuron (LMN) signs.
The vast majority of ALS cases are pathologically characterized by the deposition of abnormal ubiquitinated inclusions immunoreactive to transactive response DNA-binding protein 43 (TDP-43). ALS with TDP-43 pathology features axonal phosphorylated TDP-43 (pTDP-43) aggregates predominantly located in the facial and hypoglossal nuclei and anterior horn cells.
Neurologists at the National Hospital Organization Kure Medical Center and Chugoku Cancer Center (Kure, Japan) and their colleagues examined how to identify and characterize the histopathology of peripheral axons in the skeletal muscle of patients with ALS. The study was composed of two parts: a retrospective population-based cohort, which included 114 patients (mean age 62.3 years, 67% male) who underwent open muscle biopsy from January 1, 2004 to September 30, 2019 with a minimum one year of follow-up, and a case-control portion, which included 10 patients diagnosed with sporadic ALS (SALS) and TDP-43 pathology after postmortem muscle tissue examination, as well as 12 control participants with non-ALS diagnosis.
All muscle biopsy specimens were frozen in liquid nitrogen–cooled isopentane for histochemistry and immunohistochemistry. For each muscle specimen, 8-μm transverse sections were subjected to histochemistry and immunohistochemistry. These sections were immunostained using a Ventana BenchMark GX automated slide staining system (Ventana Medical Systems, Oro Valley, AZ, USA) with a mouse monoclonal pTDP-43 antibody. Immunofluorescence detection was performed on 8-μm transverse sections at 50-μm intervals and sections were photographed using a BIOREVO BZ-9000 fluorescence microscope (Keyence, Milton Keynes, UK).
The scientists reported that among 114 patients in the cohort study, 71 (62.3%) exhibited intramuscular nerve bundles. In those who exhibited pTDP-43-positive intramuscular nerve bundles, 33 patients (22 male, mean age, 65.2 years) were later diagnosed with ALS. The other 38 patients (26 male) showed no pTDP-43-positive bundles and did not develop ALS. Data additionally revealed that in patients lacking evident nerve bundles (28 male, mean age, 61.3 years), three were later diagnosed with ALS. Among patients with ALS in the biopsy cohort, nine with pTDP-43–positive bundles showed only lower motor neuron symptoms at biopsy.
Takashi Kurashige, MD, PhD, of the department of neurology and a senior author of the study said, “The vast majority of sporadic ALS (SALS) cases are pathologically characterized by the deposition of abnormal ubiquinated inclusions immunoreactive to TDP-43.”
The authors concluded that axonal pTDP-43 accumulations may be characteristic for patients with ALS, and as a result, may be a novel diagnostic biomarker for ALS. Axonal pTDP-43–positive accumulations were detected not only in the nerve bundles of patients with autopsy-confirmed SALS, but also in those of patients with SALS who had only lower motor neuron symptoms as clinical manifestations at the time of biopsy. The study was published on May 23, 2022 in the journal JAMA Neurology.
Related Links:
National Hospital Organization Kure Medical Center and Chugoku Cancer Center
Ventana Medical Systems
Keyence
